Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

New antiplatelet agents in the pipeline at Astra

Oct. 22, 1998

DuPont discloses heteroaromatic factor Xa inhibitors

Oct. 22, 1998

FDA Cardiovascular and Renal Drugs Advisory Committee meets this week

Oct. 20, 1998

Phase I study results reported for rNAPc2; further testing of novel anticoagulant recommended

Oct. 20, 1998

5-HT2A receptor antagonist shows potent antithrombotic activity in rat model

Oct. 19, 1998

Orally active thrombin inhibitors prepared at ADIR as anticoagulants

Oct. 19, 1998

Heterocyclic anticoagulants in development at BioChem Pharma

Oct. 15, 1998

Low-dose xemilofiban + high-dose ASA provides protection in canine arterial thrombosis model

Oct. 9, 1998

Sibrafiban interactions studied in canine model

Oct. 9, 1998

Rovi introduces LMW heparin in Spain

Oct. 7, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.